Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence of Device-Related Thrombosis in Watchman Patients Undergoing a Genotype-Guided Antithrombotic Strategy.

JACC. Clinical electrophysiology - 1 Dec 2021

Della Rocca Domenico G, Horton Rodney P, Di Biase Luigi, Gianni Carola, Trivedi Chintan, Mohanty Sanghamitra, Anannab Alisara, Magnocavallo Michele, Chen Qiong, Tarantino Nicola, Bassiouny Mohamed, Lavalle Carlo, Natale Veronica N, Forleo Giovanni B, Del Prete Armando, Van Niekerk Christoffel Johannes, Al-Ahmad Amin, Burkhardt J David, Gallinghouse G Joseph, Sanchez Javier E, Lakkireddy Dhanunjaya, Gibson Douglas N, Natale Andrea

Abstract excerpt

OBJECTIVES: This study sought to report the incidence of device-related thrombosis (DRT) and thromboembolic (TE) events when an alternative to clopidogrel is prescribed in loss-of-function (LOF) allele carriers of the cytochrome P450 2C19 (CYP2C19) gene. BACKGROUND: LOF polymorphisms of the CYP2C19 gene are associated with reduced hepatic bioactivation of clopidogrel. METHODS: A total of 1,002 Watchman patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fibrinolytic Agents

Share to Genotype

Share to Incidence

Share to Thrombosis

Source

Identifiers

PMID: 34217665
DOI: 10.1016/j.jacep.2021.04.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence of Device-Related Thrombosis in Watchman Patients Undergoing a Genotype-Guided Antithrombotic Strategy.PMID 34217665Read ↗

CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).Semantic proximity Read ↗

[Genotype-guided antithrombotic therapy].Semantic proximity Read ↗

A Genotype-Guided P2Y12-Inhibitor De-Escalation Strategy in Acute Coronary Syndrome: Observational Evidence from the POPULAR-GUIDE PCISemantic proximity Read ↗

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Semantic proximity Read ↗

Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.Semantic proximity Read ↗

Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.Semantic proximity Read ↗

A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCISemantic proximity Read ↗

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Semantic proximity Read ↗

CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.Semantic proximity Read ↗

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.Semantic proximity Read ↗

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.